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Abstract 
Introduction: Epidemiological studies indicate an association between type 2 diabetes and pancreatic 
cancer but the complex and multidirectional relationship between them remains unclear. 
Areas covered: We summarized epidemiological evidence on diabetes and pancreatic cancer exploring the 
time-risk relationship. We described mechanisms linking long-standing diabetes to pancreatic cancer. We 
discussed pancreatic cancer-associated diabetes and its implication in the early detection of pancreatic 
cancer. 
Expert opinion: The markedly increased risk of pancreatic cancer in patients with new-onset diabetes 
compared with long-standing diabetes indicates a complex and bidirectional connection, with long-standing 
diabetes being a predisposing factor for pancreatic cancer (increasing the risk of the malignancy 1.5- to 2-
fold) and new-onset diabetes an early manifestation of the tumour. Identifying clinical features and 
biomarkers to distinguish pancreatic cancer-associated diabetes from type 2 diabetes is an important goal 
to improve management and survival of this cancer. Imaging (MRI) for middle age patients with new-onset 
diabetes may be considered. 
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Article highlights 
• Pancreatic cancer is frequently recognized at an advanced stage and has a dismal prognosis. 
• Epidemiological studies indicate a complex and multidirectional relationship between type 2 diabetes 
and pancreatic cancer. 
• The risk of pancreatic cancer is greatest early after the diagnosis of diabetes and then it decreases, 
while remaining elevated many years after the diagnosis. 
• Time-related aspects of the association between diabetes and pancreatic cancer suggest that long-
standing diabetes is a risk factor for pancreatic cancer, increasing the risk 1.5- to 2-fold, while new-
onset diabetes is an early manifestation of the tumour. 
• Possible mechanisms for a direct link between long-standing diabetes and pancreatic cancer include 
resistance and compensatory hyperinsulinemia, elevated levels of circulating insulin-like growth 
factors, hyperglycemia and low chronic inflammation. 
• The association between long-standing diabetes and pancreatic cancer may be in part due to shared 
risk factors between such two conditions, namely overweight/obesity, as well as to the increased 
medical surveillance of patients with a diagnosis of diabetes or pancreatic cancer.  
• Pancreatic cancer-associated diabetes is likely a paraneoplastic effect. 
• Diabetes caused by pancreatic cancer may be a clinical marker of underlying asymptomatic cancer. 
Identify clinical features and biomarkers to distinguish cancer-associated from type 2 diabetes may 
allow for earlier detection of pancreatic cancer, and hence improve management and survival.  
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1. Introduction 
Over 90% of pancreatic cancers are adenocarcinomas of the exocrine pancreas. The adenocarcinoma of the 
exocrine pancreas is an aggressive tumor frequently recognized at advanced stage [1]. Therapies often have 
an unsatisfactory impact and the 5-year relative survival rate is <10% (~3% for metastatic cancer) [2]. In 
contrast to most other cancers, mortality due to pancreatic cancer has not declined over the most recent 
years [3-6].  
Tobacco smoking is an established cause for pancreatic cancer [7], being responsible for 15-25% of cancers 
in various populations [7-10]. Other risk factors include history of (chronic) pancreatitis, obesity, diabetes 
and metabolic syndrome, heavy alcohol consumption and, possibly, selected aspects of diet [11-13], 
although the issue of diet and pancreatic cancer remains largely unclear.  
The association between diabetes mellitus and pancreatic cancer has been  noted since the mid’ 1800s 
[14], yet the complex and multidirectional relationship remains unclear. A higher than 2-fold increase in risk 
of pancreatic cancer was reported by earlier studies for diabetic patients compared to individuals without 
diabetes [15-18]. A real association is likely to exist [19], although this is probably more modest than 
previously supposed [20]. Studies assessing time-related aspects consistently indicate a negative 
relationship between diabetes duration and the risk of pancreatic cancer, with a peak rise in risk early after 
the diagnosis of diabetes that progressively decreases, while remaining elevated for many years. Such 
observations suggest bidirectional causality, indicating that diabetes is associated with an increased risk of 
pancreatic cancer and which may  be the result of (subclinical) malignancy [21]. 
We herein summarize meta-analyses on the association between diabetes (mainly diabetes type II) and 
pancreatic cancer and discussed the largest original epidemiological studies that have been published over 
recent years, with the aim of providing a quantification of the association, and of the related time-risk 
relationship. We also discussed mechanisms linking long-standing diabetes to pancreatic cancer, pancreatic 
cancer-associated diabetes and its potential implications in the early detection of this cancer.  
 
2. Epidemiological studies on diabetes and pancreatic cancer 
Since the 1980s, several studies investigated the association between type 2 diabetes and the risk of 
pancreatic cancer. Findings of these studies have been reviewed and summarized in various reports 
[11,19,20,22-29], including at least 5 meta-analyses [20,22-24,27] (Table 1).  
A meta-analysis, published in 1995, found a doubled risk for subjects with diabetes based on 20 studies 
[22]. In 2005, a meta-analysis of 36 studies estimated a summary relative risk (RR) of pancreatic cancer of 
1.82 (95% confidence interval, CI, 1.66-1.89) for diabetic patients compared to non-diabetics [20]. Patients 
diagnosed with diabetes within 4 years prior to cancer diagnosis had a 50% greater risk of pancreatic cancer 
compared to patients with a longer history of the disease. The RR of patients with diabetes for 10 years or 
over was around 1.5. A subsequent meta-analysis of 35 cohort studies showed a summary RR for diabetes 
of 1.94 (95% CI, 1.66–2.27) with the results being consistent after body mass index (BMI) and smoking 
adjustment. This meta-analysis also found an inverse relationship between the duration of diabetes and the 
risk of pancreatic cancer [23]. Based on 50 cohort and 39 case-control studies published up to 2013, 
Batabyal. et al [24] estimated a summary RR of pancreatic cancer for diabetic subjects of 1.97 (95% CI, 1.78-
2.18). This was similar in studies adjusting for smoking or not. As in the previous reports, the risk of 
pancreatic cancer was markedly increased after diabetes diagnosis; it then decreased, but remained 
elevated by 36% long after the diagnosis. Another meta-analysis, published in 2015, found a 60% increased 
pancreatic cancer risk for duration of diabetes ≥2 years versus no diabetes. For diabetes duration ≥10 years, 
there was a 50% increase in risk [27]. Publication bias did not affect those results [23,27].  
In 2015, an umbrella review on type 2 diabetes and cancer [30] reported that the association with diabetes 
was not convincing for pancreatic cancer, as well as for a number of other cancer types. A likely explanation 
was the use of very stringent criteria to define a valid and “robust” association [31]. Specifically, pancreatic 
cancer was not included among cancers with convincing association with diabetes mainly because the 95% 
prediction interval included unity [23]. 
Since the publication of the last meta-analysis, several epidemiological investigations have become 
available. Among them, a pooled analysis of 15 case–control studies (Pancreatic Cancer Case-Control 
Consortium, Panc4), 9 of which already considered in the previous meta-analysis by Batabyal et al [24], 
included about 8300 cases and almost 14,000 controls and estimated an overall odds ratio (OR) of 1.90 
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(95% CI, 1.72–2.09) for history of diabetes 2 or more years before cancer diagnosis, after allowance for the 
most relevant risk factors for pancreatic cancer, including BMI, alcohol, smoking and history of pancreatitis 
[32]. The association between diabetes and pancreatic cancer was independent from BMI and smoking. 
Pancreatic cancer risk decreased as time since diagnosis of diabetes increased, with a ten-fold excess risk 
for new onset diabetes and a significant 30% elevated risk still evident 20 or more years after diabetes 
diagnosis. The ORs for diabetes duration were 10.32 (95% CI, 7.48–14.23) for <1 year, 3.68 (95% CI, 2.84–
4.77) for 1 to <2 years, 2.92 (95% CI, 2.44–3.50) for 2 to <5 years,  1.84 (95% CI, 1.54–2.20) for 5 to <10 
years, 1.69 (95% CI, 1.36–2.09) for 10 to <15 years, 1.54 (95% CI, 1.17–2.03) for 15 to <20 years, and 1.30 
(95% CI, 95% CI 1.03–1.63) for 20 years or over.  
A further pooled analysis of 19 cohorts within the Asia Cohort Consortium (including the JACC [33,34] and 
JPHC cohorts [35], already considered in previous meta-analyses [24,27]), including data from over 770,000 
participants and 2546 deaths from pancreatic cancer, found an overall hazard ratio (HR) of pancreatic 
cancer death of 1.53 (95% CI, 1.32-1.77), after the allowance for major confounders, including BMI and 
smoking [36]. The corresponding HR after excluding the first 3 years of follow-up was 1.57 (95% CI, 1.34-
1.83). Although information on the type of diabetes was not available, it is likely that type 2 diabetic 
patients represented the large majority of diabetics in the dataset, since type 1 diabetes accounts for less 
than 3% of total diabetes in Asia [37]. In that pooled-analysis, the association between diabetes and 
pancreatic cancer death was somewhat stronger among individuals with BMI<22.8 kg/m2. In any case, the 
HR for diabetes remained significantly elevated even among individuals with a higher BMI. In addition, the 
risk of pancreatic cancer death was (nonsignificantly) higher when duration of diabetes at baseline was <5 
years (HRs 1.62 for <5 years and 1.21 for a longer duration). 
The US Women's Health Initiative (WHI) observational study [38], based on over 156,000 postmenopausal 
women and 1000 pancreatic cancer cases, estimated a moderate increased HR for diabetes after the 
allowance for waist circumference (HR: 1.30, 95% CI, 1.01-1.66). 
In addition, several cohorts based on administrative datasets or cancer/diabetes registries have been 
recently published [39-49]. While offering important advantages in terms of sample size and 
representativeness of the populations, such studies were shadowed by the limited availability of 
information on confounding factors, specifically tobacco smoking and BMI. Those studies generally 
confirmed the direct association between diabetes and pancreatic cancer, with RR estimates for any 
duration of diabetes of the order of 2.0-3.0. Some of them also supported the inverse association with time 
since diabetes diagnosis [40,41,43,47,49]. In particular, in a cohort of 2.3 million adults from a health 
maintenance organization in Israel, with almost 2000 incident cases of pancreatic cancer, the HR of 
pancreatic cancer was over 15 in the first year following diabetes diagnosis, over 5 in years 1-<2 and around 
3 (still significant) in years 2–11 following diabetes diagnosis [41]. In addition, an updated of a nationwide 
Swedish cohort based on over 380,000 individuals with a diagnosis of type 2 diabetes in the period 1964-
2010 and 2027 incident pancreatic cancers found standardized incidence ratios (SIR) decreasing as follow-
up increased, ranging from 8.8 for <1 year to 1.47 (still significant) for 10 years and over [47].  
Two recent meta-analyses addressed possible sex differences in the association between diabetes and 
pancreatic cancer [25,50]. Based respectively on 24 [25] and 31 cohorts [50], they found similar RRs of 
pancreatic cancer in diabetic men and women.  
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3. Expert opinion 
Epidemiological evidence indicates a direct association between type 2 diabetes and pancreatic cancer and 
supports an inverse relation with diabetes duration. In particular, the observed risk of pancreatic cancer is 
greatest early after the diagnosis of diabetes and it progressively decreases, while remaining elevated many 
years after diabetes detection. The markedly higher risk of pancreatic cancer in patients with new-onset 
diabetes compared with long-standing diabetes suggests a complex and bidirectional connection: on one 
side, long-standing diabetes is a predisposing factor for pancreatic cancer development, increasing the risk 
of the malignancy around 1.5- to 2-fold; on the other side, new-onset diabetes may be a consequence or an 
early manifestation of pancreatic cancer [51]. In the latter context, diabetes secondary to pancreatic cancer 
usually develops within 24-36 months prior to the diagnosis of the cancer [52].  
 
3.1 Long-standing diabetes 
Several mechanisms have been suggested to clarify the association between long-standing diabetes and 
pancreatic cancer.  
A hypothesis includes insulin resistance and compensatory high levels of insulin secretion (overproduced in 
type 2 diabetes mellitus until β-cell failure) [51,53]. In a pooled-analysis of 5 US prospective cohorts, the 
RRs for the upper versus lower quintile were 1.57 (95% CI, 1.08-2.30) for prediagnostic serum insulin and 
2.22 (95% CI, 1.50-3.29) for prediagnostic proinsulin. Such associations became progressively stronger 
considering only cases developed after 5 or 10 years of follow-up, indicating that elevated biomarkers were 
not likely due to preclinical cancer [54]. Similarly, a prospective study estimated a two-fold pancreatic 
cancer risk (95% CI, 1.0-3.9) among individuals in the upper versus the lower quartile of insulin level, after 
excluding patients diagnosed within the first 5 years of follow-up, and also reported direct associations with 
baseline insulin resistance and higher glucose concentration [55]. Again, the associations were stronger 
after a longer time of follow-up. A role of hyperinsulinemia in the risk of pancreatic cancer is also supported 
by the observation that obese patients undergoing bariatric surgery (who typically show hyperinsulinemia) 
had a 50% reduction in the risk of pancreatic cancer compared to obese nonsurgical patients [56].  
Both a direct effect of insulin and an indirect action involving growth hormone (GH)/insulin-like growth 
factor (IGF) axis could explain the increase in risk of hyperinsulinemic patients. Pancreatic β-cells release 
insulin in the intrapancreatic portal vessels [51] that lap acinar and ductal cells [57]. Thus, insulin exerts a 
proxicrine effect on receptors of exocrine pancreatic cells that, once activated, convey survival and 
proliferation signals [19] involved in carcinogenesis [58]. Insulin may also indirectly promote 
cancerogenesis acting on GH/IGF axis [19]. IGF receptors, expressed in pancreatic cancer cells, codify 
antiapoptotic and angiogenic signals which promote tumor development. Insulin increases levels of free 
and bioactive IGF-1, reducing hepatic production of IGF binding protein (IGFBP). Further, IGF-1 and insulin 
receptors are structurally similar, thus insulin and IGF-1 could activate both receptors. High IGF1 and 
hyperinsulinemia, that occurs in insulin resistant individuals, act synergically in promoting cancerogenesis 
[28]. In line with the hyperinsulinemic hypothesis [53], treatments improving insulin resistance, namely 
metformin, might reduce pancreatic cancer risk, whereas therapies that stimulate endogenous release of 
insulin, such as sulfunylureas, may increase the risk [59], although evidence is unclear [60].  
In addition, a possible role of hyperglycemia in the diabetes-pancreatic cancer association has been 
suggested [28,53]. Hyperglycemia can attenuate antioxidant enzyme activity and enhance free radical 
formation, leading to a state of oxidative stress. Hyperglycemia is associated with increased levels of 
advanced glycation end products (AGE), whose receptor binds several ligands implicated in inflammation 
and cancer process [51]. Moreover, hyperglycaemic conditions may facilitate neoplastic proliferation [61]. 
Nonetheless, glucose uptake mechanisms may not add a further growth advantage [19].  
Overweight, that frequently characterized type 2 diabetes, could play a crucial role in carcinogenesis 
[62,63]. Adipose tissue is a complex endocrine organ able to secrete a variety of bioactive molecules 
(cytokines, free fatty acids, TNFalfa, plasminogen activator inhibitor-1 (PAI-1) and adiponectin) which may 
lead malignant transformation and progression [64]. Further, adipose tissue microenvironment promotes 
concomitant systemic endocrine alterations (obesity-related insulin resistance, hyperinsulinemia, sustained 
hyperglycemia) which, in turn, are involved in cancer development [65]. However, an increased risk of 
pancreatic cancer among diabetic subjects was evident also after adjusting for anthropometric factors 
(mainly BMI) [7,23,36,38] and in subgroup defined by BMI [7,36], thus indicating that obesity is unlikely to 
Ac
ce
pte
d M
an
us
cri
pt
 
 
Information Classification: General 
explain the observed association, although some degree of under-adjustment is possible. Further, RRs for 
the diabetes-pancreatic cancer association are similar in studies adjusting and not adjusting for smoking 
[23,24]. In addition, the direct association between prediabetes and pancreatic cancer risk [66] supports 
the relationship between diabetes and pancreatic cancer. 
Diagnostic bias may contribute in part to the observed increased risk. Indeed, an increased medical 
surveillance has been documented for patients with type 2 diabetes [67]. 
The risk of the malignancy declines with the increasing duration of diabetes. Such downward trend in risk 
might be explained through a decreased role of diagnostic bias, besides a possible additional role of a 
decreased secretion of endogenous insulin, lifestyle changes after diabetes diagnosis and the use of 
metformin and selected glucose-lowering medications. 
 
3.2 New onset diabetes  
The risk of pancreatic cancer is highly increased until a couple of years from diabetes diagnosis, suggesting 
that the cancer itself lead to the onset of diabetes.  
Pancreatic cancer-induced diabetes has been classified as pancreatogenic type 3c diabetes mellitus [68]. 
However, only a small proportion (<10%) of type 3c diabetes (which accounts for <10% of total diabetes) is 
attributed to pancreatic neoplasia, while the majority (75-80%) is associated to chronic pancreatitis [51]. 
Concurrent diabetes and chronic pancreatitis increased the risk of pancreatic cancer by 5- to over 30-fold 
[69-71].  
The hypothesis that pancreatic cancer induces diabetes is supported by the observations that roughly half 
of the newly diagnosed pancreatic cancer patients have diabetes at the time of diagnosis, which is 
frequently (>50%) new-onset having developed over the 2-3 years preceding the diagnosis of pancreatic 
cancer [52,72]. Not all new onset diabetes is type 3c diabetes mellitus (assuming that type 3c diabetes 
mellitus is a well-defined, independent syndrome), but, in a proportion of patients with new-onset 
diabetes, resection of the tumor is followed by diabetes resolution [72]. In an Italian multicentric case-
control study, diabetes was diagnosed concomitantly with pancreatic cancer in 40% of patients and within 
2 years before the diagnosis of cancer in 16% [73].  
The physiopathology linking type 3c diabetes mellitus to pancreatic cancer is still poorly understood. 
Diabetes secondary to pancreatic cancer may be the result of a glandular destruction due to tumour 
infiltration and ductal obstruction. However, diabetes in pancreatic cancer patients is mainly characterized 
by hyperinsulinemia secondary to insulin resistance. Therefore, diabetes secondary to pancreatic cancer is 
likely a paraneoplastic effect: mediators released by the cancer interfere with insulin secretion or insulin 
action [74]. This is supported by the evidence that treatments (resection or chemotherapy) of pancreatic 
cancer often lead to improvement in hyperglycemia [72]. In addition, a direct role of pancreatic cancer in 
new onset diabetes is supported by the finding that glucose tolerance improves after tumour treatment in 
patients with new-onset diabetes secondary to pancreatic cancer, whilst it does not improve in long-
standing diabetes [75].   
In any case, the peak of pancreatic cancer risk within the first years since diabetes detection may be 
inflated by the heightened surveillance following diabetes diagnosis.  
 
3.3 New onset diabetes for the early detection of pancreatic cancer  
The 5-year relative survival rate of pancreatic cancer is around 5%, and ranges between around 35% for 
localized cancers (which represent a small fraction of cancers) and 3% for metastatic ones [2]. The 
detection of pancreatic cancer is often delayed because symptoms are often aspecific (e.g., weight loss, 
jaundice, nausea) and occur in an advanced stage. Thus, early detection of pancreatic cancer when it is still 
asymptomatic, and therapeutic options are available, is an important goal for improving pancreatic cancer 
management and survival. 
New-onset diabetes caused by the cancer is a possible clinical marker of underlying asymptomatic 
pancreatic cancer. Therefore, the identification of patients with cancer-associated diabetes could offer the 
opportunity for the early detection of the malignancy [68]. According to a population-based cohort study, 
the 3-year cumulative incidence of pancreatic cancer among newly diagnosed diabetic patients aged ≥50 
years was 0.85%, over 6-fold higher than the general population [76]. Although mass screening for 
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pancreatic cancer in all patients with new-onset diabetes is still open to discussion [77], imaging (MRI) of 
the pancreas may be considered for middle age and elderly subjects (≥50 years) developing diabetes. Some 
further indications to distinguish pancreatic cancer-associated diabetes from other types of diabetes may 
derive from clinical features atypical for type 2 diabetes, such as rapidly altered glycemic indices, weight 
loss in the preceding months prior to diabetes onset, absence of typical characteristics of the metabolic 
syndrome, and family history [74]. Notably, a case-control study indicated that elevated glucose levels 
precede the diagnosis of pancreatic cancer by 30-36 months [78]. 
Two studies developed and validated clinical prediction models to identify high-risk individuals among 
those with newly diagnosed diabetes who might benefit from pancreatic cancer screening. One clinical 
model included age at diabetes diagnosis and change in weight and in blood glucose and stratified patients 
in 3 risk groups. The cut-off for the very high-risk group had sensitivity and specificity of 80% [79]. A further 
model was based on age, BMI, change in BMI, smoking, use of antidiabetic medications, serum levels of 
HbA1C, and other selected markers, and had 45% sensitivity and 94% specificity, and a positive predictive 
value of 2.6% [80]. However further validation is need.    
It is likely that a combination of biomarkers and clinicopathologic characteristics of diabetic patients is 
useful in early cancer detection. Although no biomarker is currently validated to differentiate between type 
2 diabetes and cancer-associated diabetes, evidence shows the potential relevance of some molecules [81]. 
In particular, the most convincing ones include Vanin-1 (VNN1) [82], Adrenomedullin [83], CA19-9 and CEA 
[84], glucagon/insulin ratio [85] and a deficient pancreatic polypeptide (PP) response to nutrient ingestion 
[86]. 
Future research may identify predictive models and/or sensitive and specific biomarkers for the 
identification of occult pancreatic cancer in patients with new-onset diabetes, and develop an efficient and 
cost-effective interventional screening protocol for newly diagnosed diabetic patients that includes imaging 
and/or clinical algorithms. In this context, valuable data may be generated in the next years by the 
Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC). Initiated in 
2015, the CPDPC aims to assemble a cohort of 10,000 subjects ≥50 years with new onset diabetes to 
address to the challenges posed by early detection of pancreatic cancer [87].  
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Table 1. Summary of major meta-analyses examining the association between diabetes mellitus and pancreatic cancer. 
Reference N. of included studies Summary RR (95% CI) for diabetes Heterogeneity (p; I2) Summary RR (95% CI) for time since 
diabetes (years) 
Song et al, 2015 [27] 
 
26 cohort§ 
18 case-control 
 
≥2 years since diabetes: 
overall: 1.64 (1.52-1.78) 
cohort: 1.56 (1.42-1.71) 
nested: 1.88 (1.53-2.30) 
case-control: 1.75 (1.44-2.12) 
 
 
overall: p<0.001; 52.1% 
cohort: p=0.001; 54.6% 
nested: p=0.679; 0% 
case-control: p=0.004; 52.9% 
≥5 (26 studies): 1.58 (1.41-1.75) 
≥10 (14 studies): 1.50 (1.28-1.75) 
 
Batabyal et al, 2014 [24] 50 cohort§ 
39 case-control 
overall: 1.97 (1.78–2.18) 
cohort: 1.88 (1.71-2.07) 
case-control: 2.08 (1.87-2.32)  
overall: NA 
cohort: <0.001; 91%;  
case-control: <0.001; 65% 
<1 (3 studies): 6.69 (3.80- 11.78) 
1-4 (21 studies) : 1.86 (1.56-2.21) 
5-9 (23 studies): 1.72 (1.47-2.00) 
≥10 (28 studies): 1.36 (1.19-1.55)  
 
Ben et al, 2011 [23] 35 cohort§ cohort: 1.94 (1.66–2.27) cohort: p<0.001; 93.6% <1 (3 studies): 5.38 (3.49-8.30) 
1-4 (5 studies): 1.95 (1.65-2.31) 
5-9 (4 studies): 1.49 (1.05-2.12) 
≥10 (4 studies): 1.47 (0.94-2.31) 
 
>1 (14 studies): 1.96 (1.60-2.40) 
>5 (11 studies): 1.83 (1.38-2.43) 
 
Huxley et al, 2005 [20] 19 cohort§ 
17 case-control  
overall: 1.82 (1.66-1.89) 
cohort: 1.73 (1.59-1.88) 
case-control: 1.94 (1.53-2.46) 
overall: NA 
cohort: p=0.05 
case-control: p=0.002 
<4 (9 studies): 2.05 (1.87-2.25) 
5-9 (9 studies): 1.54 (1.31-1.81) 
≥10 (7 studies): 1.51 (1.16-1.96) 
 
Everhart & Wright, 1995 
[22] 
9 cohort§ 
11 case-control 
>1 year since diabetes: 
overall: 2.1 (1.6-2.8) 
cohort: 2.6 (1.6-4.1) 
case-control: 1.8 (1.1-2.7) 
 
overall: p=0.003 
cohort: NA 
case-control: NA 
≥5 (11 studies): 2.0 (1.2-3.2) 
§ Including nested case-control studies. NA: not available. 
 
